Organometallic complexes: New tools for chemotherapy

Current Medicinal Chemistry

Volumn 17, Issue 25, 2010, Pages 2729-2745

  Chavain, N ^a   Biot, C ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIV LILLE   (France)

Author keywords

Bioorganometallic chemistry; Chemotherapy; Metallocenes; Organometallic complexes

Indexed keywords

ANSA TITANOCENE DERIVATIVE; ANTINEOPLASTIC AGENT; ARSPHENAMINE; ARTEMISININ; BENZENE; CHLOROQUINE; CISPLATIN; FERROCENE; FERROCENE DERIVATIVE; FERROCIFEN DERIVATIVE; FERROCIPHEN DERIVATIVE; FERROCIPHENOL DERIVATIVE; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; MEFLOQUINE; MEPACRINE; NILUTAMIDE; OXALI TITANOCENE Y; QUININE; RUTHENOCENE DERIVATIVE; TAMOXIFEN; THIOSEMICARBAZONE; TITANOCENE; TITANOCENE C; TITANOCENE DICHLORIDE; TITANOCENE Y; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; TESTIS CANCER;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; FERROUS COMPOUNDS; HUMANS; METALS; ORGANOMETALLIC COMPOUNDS; RECEPTORS, DOPAMINE;

EID: 77955613063     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791859306     Document Type: Article

References (171)

1. Van Staveren, D. R.; Metzler-Nolte, N. Bioorganometallic chemistry of ferrocene. Chem. Rev., 2004, 104, 5931-5985.
2. Hartinger, C. G.; Dyson, P. J. Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem. Soc. Rev., 2009, 38, 391-401.
3. Beck, W.; Severin, K. Ein faszinierendes Forschungsgebiet Biometallorganische Chemie. Chem. Unserer Zeit, 2002, 36, 356-365.
4. Top, S.; Jaouen, G.; VessiLres, A.; Abjean, J. P.; Davoust, D. Rodger, C. A.; Sayer, B. G.; McGlinchey, M. J. Chromium tricarbonyl complexes of estradiol derivatives; differentiation of α and β diastereomers using 1 and 2 dimensional NMR spectroscopy at 500 MHz. Organometallics, 1985, 4, 2143-2150.
5. Meggers, E. Targeting proteins with metal complexes. Chem. Commun., 2009, 1001-1010.
6. Meggers, E. Exploring biologically relevant chemical space with metal complexes. Curr. Opin. Chem. Biol., 2007, 11, 287.
7. Miessler, G. L.; Tarr, D. A: In Inorganic Chemistry. Coordination Chemistry I: Structures and Isomers. Prentice Hall, 3rd edition, 2003.
8. Debreczeni, J. E.; Bullock, A. N.; Atilla, G. E.; Williams, D. S. Bregman, H.; Knapp, S.; Meggers, E. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew. Chem. Int. Ed. Engl., 2006, 45, 1580-1585.
9. Atilla-Gokcumen, G. E.; Williams, D. S.; Bregman, H.; Pagano, N.; Meggers, E. Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3. Chem Bio Chem, 2006, 7, 1443-1450.
10. Köpf-Maier, P.; Klapötke, T. Tumor inhibition by ferricenium complexes. Activity against some solid experimental tumors. Arzneimittelforschung, 1989, 39, 369-371.
11. Joy, A. M.; Goodgame, D. M.; Stratford, I. J. High efficiency of ferricenium salts as radiosensitizers of V79 cells in vitro and the KHT tumor in vivo. Int. J. Radiat. Oncol. Biol. Phys., 1989, 16, 1053-1056.
12. Di Gleria, K.; Hill, H. A.; Wong, L. L. N-(2-ferroceneethyl) maleimide: a new electroactive sulphydryl-specific reagent for cysteine-containing peptides and proteins. FEBS Lett., 1996, 390, 142-144.
13. Buchwald, P.; Bodor, N. Octanol-water partition: searching for predictive models. Curr. Med. Chem., 1998, 5, 353-380.
14. Abraham, M. H.; Benjelloun-Dakhama, Gola, J. M. R.; Acree, Jr., W. E., Cain, W. S.; Cometto-Muniz, J. E. Solvation descriptors for ferrocene, and the estimation of some physicochemical and biochemical properties. New J. Chem., 2000, 24, 825-829.
15. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-699.
16. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. Nature, 1969, 222, 385-386.
17. Köpf-Maier, P. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma. Anticancer Res., 1999, 19, 493-504.
18. Meléndez, E. Titanium complexes in cancer treatment. Crit. Rev. Oncol. Hematol., 2002, 42, 309-315.
19. Caruso, F.; Rossi, M. Metal Ions in Biological Systems. 2004, 42, 353-384
20. Guo, M.; Guo, Z.; Sadler, P.J. Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride. J. Biol. Inorg. Chem., 2001, 6, 698-707.
21. Guo, M.; Sun, H.; McArdle, H.J.; Gambling, L.; Sadler, P.J. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry, 2000, 39, 10023-10033.
22. Singh, M. Transferrin As A targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des., 1999, 5, 443-451.
23. Mross, K.; Robben-Bathe, P.; Edler, L.; Baumgart, J.; Berdel, W. E.; Fiebig, H.; Unger C. Phase I clinical trial of a day-1, -3, -5 every 3 weeksphase i clinical trial of day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (MKT 5) in Patients with advanced cancer. (Phase I Study Group of the AIO of the German Cancer Society). Onkologie, 2000, 23, 576-579.
24. Eisch, J.; Shi, X.; Owuor, F. Novel synthesis of ansa-metallocenes via the reductive dimerization of fulvenes with group 4 metal divalent halides. Organometallics, 1998, 17, 5219-5221.
25. Fox, S.; Dunne, J.P.; Tacke, M.; Gallagher J. F. Novel derivatives of ansa-titanocenes procured from 6-phenylfulvene: a combined experimental and theoretical study. Inorg. Chimica Acta, 2004, 357, 225-234.
26. Tacke, M.; Allen, L. T.; Cuffe, L.; Gallagher, W. M.; Lou, Y. Mendoza, O.; Müller-Bunz, H.; Rehmann, F.-J. K.; Sweeney, N. Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. J. Organomet. Chem., 2004, 689, 2242-2249.
27. Rehmann, F.-J. K.; Cuffe, L. P.; Mendoza, O.; Rai, D. K. Sweeney, N.; Strohfeldt, K.; Gallagher, W. M.; Tacke, M. Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Applied Organomet. Chem., 2005, 19, 293-300.
28. Tacke, M.; Cuffe, L. P.; Gallagher, W.M.; Lou, Y.; Mendoza, O. Müller-Bunz, H.; Rehmann, F.J.; Sweeney, N. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride. J. Inorg. Biochem., 2004, 98, 1987-1994.
29. Rehmann, F.-J.; Rous, A. J.; Mendoza, O.; Sweeney, N. J. Strohfeldt, K.; Gallagher, W. M.; Tacke, M. A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. Polyhedron, 2005, 24, 1250-1255.
30. Sweeney, N.; Mendoza, O.; Mueller-Bunz, H.; Pampillon, C.; Rehmann, K.;. Strohfeldt, K.; Tacke, M. Novel benzyl substituted titanocene anti-cancer drugs. J. Organomet. Chem., 2005, 690, 4537-4544.
31. Pampillon, C.; Mendoza, O.; Sweeney, N. J.; Strohfeldt, K.; Tacke, M. Diarylmethyl substituted titanocenes: Promising anti-cancer drugs. Polyhedron, 2006, 25, 2101-2108.
32. Pampillon, C.; Sweeney, N.; Strohfeldt, K.; Tacke, M. Diheteroarylmethyl substituted titanocenes: a novel class of potential anti-cancer drugs. Inorg. Chimica Acta, 2006, 359, 3969-3975.
33. Sweeney, N.; Gallagher, W. M.; Müller-Bunz, H.; Pampillón, C. Strohfeldt, K.; Tacke M. Heteroaryl substituted titanocenes as potential anti-cancer drugs. J. Inorg. Biochem., 2006, 100, 1479-1486.
34. Strohfeldt, K.; Müller-Bunz, H.; Pampillón, C.; Sweeney, N. J. Tacke, M. Glycol methyl ether and glycol amine substituted titanocenes as antitumor agents. Eur. J. Inorg. Chem., 2006, 26, 4621-4628.
35. Sweeney, N.; Claffey, J.; Müller-Bunz, H.; Pampillón, C. Strohfeldt, K.; Tacke, M. The synthesis and cytotoxic evaluation of a series of benzodioxole substituted titanocenes. Applied Organomet. Chem., 2007, 21, 57-65.
36. Allen, O.; Croll, L.; Gott, A. L.; Knox, R. J.; McGowan, P. C. Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organometallics, 2004, 23, 288-292.
37. Causey, P. W.; Baird, M. C.; Cole, S. P. C. Synthesis, characterization, and assessment of cytotoxic properties of a series of titanocene dichloride derivatives. Organometallics, 2004, 23, 4486-4494.
38. Meyer, R., Brinka, S.; van Rensburgb, C. E. J.; Joonéb, G. K. Görlsc, H.; Lotz, S. Synthesis, characterization and antitumor properties of titanocene derivatives with thiophene containing ligands. J. Organomet. Chem., 2005, 690, 117-125.
39. Strohfeldt K.; Tacke, M. Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chem. Soc. Rev., 2008, 37, 1174-1187.
40. Kelter, G.; Sweeney, N. J.; Strohfeldt, K.; Fiebig, H. H.; Tacke, M. In-vitro anti-tumor activity studies of bridged and unbridged benzyl- substituted titanocenes. Anti-Cancer Drugs, 2005, 16, 1091-1098.
41. Oberschmidt, O.; Hanauske, A.R.; Rehmann, F.J.; Strohfeldt, K. Sweeney, N.; Tacke M. Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units. Anti-Cancer Drugs, 2005, 16, 1071-1073.
42. O'Connor K. G. C.; Tacke, M.; Rehmann, F. J.; Strohfeldt, K. Sweeney, N.; Fitzpatrick, J. M.; Watson, R. W. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. Apoptosis, 2006, 11, 1205-1214.
43. Pampillion, C.; Sweeney, N.; Strohfeldt, K.; Ttacke, M. Synthesis and cytotoxicity studies of new dimethylamino-functionalized and heteroaryl-substituted titanocene anti-cancer drugs. Orgomet. Chem., 2007, 692, 2153-2159.
44. Hogan, M.; Claffey, J.; Fitzpatrick, E.; Hickey, T.; Pampillón, C.; Tacke, M. Synthesis and cytotoxicity studies of titanocene C analogues. Met. Based Drugs, 2008, 754358.
45. Hogan, M.; Claffey, J.; Pampillón, C.; Tacke, M. Synthesis and cytotoxicity studies of new morpholino-functionalised and Nheteroaryl- substituted titanocene anticancer drugs. Med. Chem., 2008, 4, 91-99.
46. Pampillón, C.; Claffey, J.; Hogan, M.; Tacke, M. Novel achiral titanocene anti-cancer drugs synthesised from bis-N,Ndimethylamino fulvene and lithiated heterocyclic compounds. Biometals, 2008, 21, 197-204.
47. Knüppel, S.; Wang, C.; Kehr, G.; Fröhlich, R.; Erker, G. Bis(enamino-Cp) Group 4 metal complex chemistry: developing a Mannich-type carbon-carbon coupling reaction at the bent metallocene famework. J. Organomet. Chem., 2005, 690, 14-32.
48. Hickey, T.; Claffey, J.; Fitzpatrick, E.; Hogan, M.; Pampillón, C. Tacke, M. Dimethylamino-functionalised and N-heteroarylsubstituted titanocene anticancer drugs: synthesis and cytotoxicity studies. Invest. New Drugs, 2007, 25, 425-433.
49. Jakupec, M. A.; Galanski, M.; Keppler, B. K. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 2003, 146, 1-54.
50. Riccardi, A.; Ferlini, C.; Meco, D.; Mastrangelo, R.; Scambia, G. Riccardi, R. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur. J. Cancer, 1999, 35, 86-90.
51. Claffey, J.; Hogan, M.; Müller-Bunz, H.; Pampillón, C.; Tacke, M. Oxali-Titanocene Y: A potent anticancer drug. Chem Med Chem, 2008, 3, 729-731.
52. Tamura, H.; Miwa, M. DNA cleaving activity and cytotoxic activity of ferricenium cations. Chem. Lett., 1997, 26, 1177-1178
53. Osella, D.; Ferrali, M.; Zanello, P.; Laschi, F.; Fontani, M.; Nervi, C.; Cavigiolio, G. On the mechanism of the antitumor activity of ferrocenium derivatives. Inorg. Chim. Acta, 2000, 306, 42-48.
54. Tabbi, G.; Cassino, C.; Cavigiolio, G.; Colangelo, D.; Ghiglia, A. Viano, I.; Osella, D. Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process. J. Med. Chem., 2002, 45, 5786-5796.
55. Fiorina, V. J.; Dubois, R. J.; Brynes, S. Ferrocenyl polyamines as agents for the chemoimmunotherapy of cancer. J. Med. Chem., 1978, 21, 393-395.
56. Yashchenko, G. N.; Shashmurina, A. A.; Anoshina, G. M.; Gorelova, L. A.; Evstigneeva, N. G.; Alekseeva, L. V.; Radina, L. B. Synthesis and study of the antineoplastic activity of ferrocenecontaining compounds. Khim. Farm. Zh., 1978, 12, 68-72.
57. Wenzel, M.; Schneider, M.; Liss, E. Synthesis, biochemistry and cytostatic effects of N-methyl-N-β-chloroethyl-hydrazones of metallocene aldehydes. Z. Naturforsch [C], 1979, 34, 670-676.
58. Köpf-Maier, P.; Köpf, H.; Neuse, E. W. Ferrocenium Salts - The First Antineoplastic iron compounds. Angew. Chem. Int. Ed. Engl., 1984, 23, 456-457.
59. Köpf-Meier, P.; Köpf, H.; Neuse, E. W. Ferricenium complexes - a new type of water-soluble antitumor agents. J. Cancer Res. Clin. Oncol., 1984, 108, 336-340.
60. Neuse, E. W.; Kanzawa, F. Evaluation of the activity of some water-soluble ferrocene and ferricenium compounds against carcinoma of the lung by the human tumor clonogenic assay. Appl. Organomet. Chem., 1990, 4, 19-26.
61. Swarts, J. C.; Neuse, E. W.; Lamprecht, G. J. Synthesis and characterization of water-soluble polyaspartamide-ferrocene conjugates for biomedical applications. J. Inorg. Organomet. Polymers, 1994, 4, 143-153.
62. Swarts, J. C.; Swarts, D. M.; Maree, D. M.; Neuse, E. W.; La Madeleine, C.; Van Lier, J. E. Polyaspartamides as water-soluble drug carriers. Part 1: Antineoplastic activity of ferrocenecontaining polyaspartamide conjugates. Anticancer Res., 2001, 21, 2033-2037.
63. Johnson, M. T.; Kreft, E.; N'Da, D. D.; Neuse, E. W.; van Rensburg, C. E. J. The cytotoxic activity of macromolecular ferrocene conjugates against the colo 320 DM human colon cancer line. J. Inorg. Organomet. Polymers, 2003, 13, 255-267.
64. Caldwell, G.; Meirim, M. G.; Neuse, E. W.; van Rensburg, C. E. J. Antineoplastic activity of polyaspartamide-ferrocene conjugates. Appl. Organomet. Chem., 1998, 12, 793-799.
65. Ong, C. W.; Jeng, J. Y.; Juang, S. S.; Chen, C. F. A ferroceneintercalator conjugate with a potent cytotoxicity. Bioorg. Med. Chem. Lett., 1992, 2, 929-932.
66. Scarcia, V.; Furlani, A.; Longato, B.; Corain, B.; Pilloni, G. Heteropolymetallic complexes of 1,1'-bis(diphenylphosphino) ferrocene (dppf). IV. Solvolytic behavior and cytostatic properties towards the KB cell-line of dppf and 1,2-bis(diphenylphosphino) ethane cis-complexes of Pt(II) and Pd(II). Inorg. Chim. Acta, 1988, 153, 67-70.
67. Hill, D. T.; Girard, G. R.; McCabe, F. L.; Johnson, R. K.; Stupik, P. D.; Zhang, J. H.; Reiff, W. M.; Eggleston, D. S. [.mu.-1,1'- Bis(diphenylphosphino)ferrocene]bis(chlorogold): synthesis, iron-57 and gold-197 Moessbauer spectroscopy, x-ray crystal structure, and antitumor activity. Inorg. Chem., 1988, 28, 3529-3533.
68. -). Inorg. Chim. Acta, 1991, 190, 165-167.
69. Bincoletto, C.; Terariol, I. L. S.; Oliveira, C. R.; Dreher, S.; Fausto, D. M.; Soufen, M. A.; Nascimento, F. D.; Caires, A. C. F. Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents. Bioorg. Med. Chem., 2005, 13, 3047-3055.
70. Ferle-Vidovic, A.; Poljak-Blazi, M.; Rapic, V.; Skare, D. Ferrocenes (F168, F169) and Fero-Sorbitol-Citrate (FSC): Potential anticancer drugs. Cancer Biother. Radiopharm., 2000, 15, 617-624.
71. Hartinger, C. G.; Nazarov, A. A.; Arion, V. B.; Giester, G.; Jakupec, M.; Galanski, M.; Keppler, B. K. Novel glucose-ferrocenyl derivatives: synthesis and properties. New J. Chem., 2002, 26, 671-673.
72. Wu, X.; Tiekink, E. R. T.; Kostetski, I.; Kocherginsky, N.; Tan, A. L. C.; Khoo, S. B.; Wilairat, P.; Go, M.-L. Antiplasmodial activity of ferrocenyl chalcones: Investigations into the role of ferrocene. Eur. J. Pharm. Sci., 2006, 27, 175-187.
73. Mooney, Á.; Corry, A. J.; O'Sullivan, D.; Rai, D. K.; Kenny, P. T. M. The synthesis, structural characterization and in vitro anticancer activity of novel N-(3-ferrocenyl-2-naphthoyl) dipeptide ethyl esters and novel N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters. J. Organomet. Chem., 2009, 694, 886-894.
74. Popova, L. V.; Babin, V. N.; Belousov, Yu A.; Nekrasov, Yu S. Snegireva, A. E.; Borodina, N. P.; Shaposhnikova, G. M.; Bychenko, O. B.; Raevskii, P. M.; Morozova, N. B.; Iiyina, A. I. Shitkov, K. G. Antitumor effects of binuclear ferrocene derivatives. Appl. Organomet. Chem., 1993, 7, 85-94.
75. Kelly, P. N.; Prêtre, A.; Devoy, S.; O'Rielly, I.; Devery, R.; Goel, A.; Gallagher, J. F.; Lough, A. J.; Kenny, P. T. M. Synthesis, structural characterisation and biological activity of novel N-(ferrocenylmethyl)benzene-carboxamide derivatives. J. Organomet. Chem., 2007, 692, 1327-1331.
76. Shago, R. F.; Swarts, J. C.; Kreft, E.; Van Rensburg, C. E. J. Antineoplastic activity of a series of ferrocene-containing alcohols. Anticancer Res., 2007, 27, 3431-3434.
77. Silva, B. V.; Ribeiro, N. M.; Pinto, A. C.; Vargas, M. D.; Dias, L. C. Synthesis of ferrocenyl oxindole compounds with potential anticancer activity. J. Braz. Chem. Soc., 2008, 19, 1244-1247.
78. Swarts, J. C.; Vosloo, T. G.; Cronje, S. J.; Du Plessis, W. C.; Van Rensburg, C. E. J.; Kreft, E.; Van Lier, J. E. Cytotoxicity of a Series of Ferrocene-containing β-Diketones. Anticancer Res., 2008, 28, 2781-2784.
79. Spencer, J.; Mendham, A. P.; Kotha, A. K.; Richardson, S. C. W. Hillard, E. A. Jaouen, G.; Male, L.; Hursthouse, M. B. Structural and biological investigation of ferrocene-substituted 3-methylidene-1,3-dihydro-2H-indol-2-ones. Dalton Trans., 2009, 6, 918-921.
80. Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem., 2003, 46, 883-908.
81. Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem., 2003, 46, 1081-1111.
82. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J. Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 1998, 95, 927-937.
83. Jaouen, G.; Top, S.; Raynaud, J.P. French Patent 2725720-AI, 1994.
84. Top, S.; Tang, J.; Vessières, A.; Carrez, D.; Provot, C.; Jaouen, G. Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics. Chem. Commun., 1996, 8, 955-956.
85. Jaouen, G.; Top, S.; Vessieres, A.; Leclercq, G.; McGlinchey, M. J. The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. Curr. Med. Chem. 2004, 11, 2505-2517.
86. Nguyen, A.; Vessieres, A.; Hillard, E. A.; Top, S.; Pigeon, P. Jaouen, G. Ferrocifens and Ferrocifenols as new potential weapons against breast cancer. Chimia, 2007, 61, 716-724.
87. Hillard, E. A.; Pigeon, P.; Vessieres, A.; Amatore, C.; Jaouen, G. The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif. Dalton Trans., 2007, 43, 5073-5081.
88. Hillard, E.; Vessieres, A.; Thouin, L.; Jaouen, G.; Amatore, C. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. Angew. Chem., Int. Ed., 2006, 45, 285-290.
89. Fan, P.W.; Zhang, F.; Bolton, J.L. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol., 2000, 13, 45-52.
90. Zhang, F.; Fan, P. W.; Liu, X.; Shen, L.; van Breemen, R. B.; Bolton, J. L. Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol., 2000, 13, 53-62.
91. Terashima, I.; Suzuki, N.; Shibutani, S. Mutagenic Potential of - (N2-Deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res., 1999, 59, 2091-2095.
92. Pigeon, P.; Top, S.; Vessières, A.; Huché, M.; Hillard, E. A.; Salomon, E.; Jaouen, G. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. J. Med. Chem., 2005, 48, 2814-2821.
93. Top, S.; Thibaudeau, C.; Vessières, A.; Brulé, E.; Le Bideau, F.; Joerger, J.-M.; Plamont, M.-A.; Samreth, S.; Edgar, A.; Marrot, J.; Herson, P.; Jaouen, G. Synthesis and structure activity relationship of organometallic steroidal androgen derivatives. Organometallics, 2009, 28, 1414-1424.
94. Payen, O.; Top, S.; Vessires, A.; Brul, E.; Plamont, M.-A.; McGlinchey, M. J.; Mller-Bunz, H.; Jaouen, G. Synthesis and structure-activity relationships of the first ferrocenyl-arylhydantoin derivatives of the nonsteroidal antiandrogen nilutamide. J. Med. Chem., 2008, 51, 1791-1799.
95. Biot, C.; Glorian, G.; Maciejewski, L. A.; Brocard, J. S. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocenechloroquine analogue. J. Med. Chem., 1997, 40, 3715-3718.
96. Biot, C.; Bauer, H.; Schirmer, R. H.; Davioud-Charvet, E. 5-substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials. J. Med. Chem., 2004, 47, 5972-5983.
97. Biot, C.; Delhaes, L.; Maciejewski, L. A.; Mortuaire, M.; Camus, D.; Dive, D.; Brocard, J. S. Synthetic ferrocenic mefloquine and quinine analoguesas potential antimalarial agents. Eur. J. Med. Chem., 2000, 35, 707-714.
98. Delhaes, L.; Biot, C.; Berry, L.; Maciejewski, L. A.; Camus, D.; Brocard, J. S.; Dive, D. Novel ferrocenic artemisinin derivatives: synthesis, in vitro antimalarial activity and affinity of binding with ferroprotoporphyrin IX. Bioorg. Med. Chem., 2000, 8, 2739-2745.
99. Paitayatat, S.; Tarnchompoo, B.; Thebtaranonth, Y.; Yuthavong, Y. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. J. Med. Chem., 1997, 40, 633-638.
100. Domarle, O.; Blampain, G.; Agnaniet, H.; Nzadiyabi, T.; Lebibi, J.; Brocard, J.; Maciejewski, L.; Biot, C.; Georges, A. J.; Millet, P. In vitro antimalarial activity of a new organometallic analog, ferrocene-chloroquine. Antimicrob. Agents Chemother., 1998, 42, 540-544.
101. Atteke, C.; Ndong, J. M.; Aubouy, A.; Maciejewski, L.; Brocard, J.; Lébibi, J.; Deloron, P. In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon. J. Antimicrob. Chemother., 2003, 51, 1021-1024.
102. Barends, M.; Jaidee, A.; Khaohirun, N.; Singhasivanon, P.; Nosten, F. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar. J., 2007, 6, 81.
103. Chim, P.; Lim, P.; Sem, R.; Nhem, S.; Maciejewski, L.; Fandeur, T. The in-vitro antimalarial activity of ferrochloroquine, measured against Cambodian isolates of Plasmodium falciparum. Ann. Trop. Med. Parasitol., 2004, 98, 419-424.
104. Kreidenweiss, A.; Kremsner, P. G.; Dietz, K.; Mordmüller, B. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg., 2006, 75, 1178-1181.
105. Pradines, B.; Fusai, T.; Daries, W.; Laloge, V.; Rogier, C.; Millet, P.; Panconi, E.; Kombila, M.; Parzy, D. Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. J. Antimicrob. Chemother., 2001, 48, 179-184.
106. Pradines, B.; Tall, A.; Rogier, C.; Spiegel, A.; Mosnier, J.; Marrama, L.; Fusai, T.; Millet, P.; Panconi, E.; Trape, J. F.; Parzy, D. In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop. Med. Int. Health, 2002, 7, 265-270.
107. Biot, C.; Daher, W.; Ndiaye, C. M.; Melnyk, P.; Pradines, B.; Chavain, N.; Pellet, A.; Fraisse, L.; Pelinski, L.; Jarry, C.; Brocard, J.; Khalife, J.; Forfar-Bares, I.; Dive, D. Probing the role of the covalent linkage of ferrocene into a chloroquine template. J. Med. Chem., 2006, 49, 4707-4714.
108. Biot, C.; Delhaes, L.; N'Diaye, C. M.; Maciejewski, L. A.; Camus, D.; Dive, D.; Brocard, J. S. Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds. Bioorg. Med. Chem., 1999, 7, 2843-2847.
109. Biot, C.; Daher, W.; Chavain, N.; Fandeur, T.; Khalife, J.; Dive, D.; De Clercq, E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem., 2006, 49, 2845-2849.
110. Biot, C.; Pradines, B.; Sergeant, M. H.; Gut, J.; Rosenthal, P. J.; Chibale, K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg. Med. Chem. Lett., 2007, 17, 6434-6438.
111. Chavain, N.; Davioud-Charvet, E.; Trivelli, X.; Mbeki, L.; Rottmann, M.; Brun, R.; Biot, C. Antimalarial activities of ferroquine conjugates with either glutathione reductase inhibitors or glutathione depletors via a hydrolyzable amide linker. Bioorg. Med. Chem., 2009, 17, 8048-8059.
112. Dubar, F.; Anquetin, G.; Pradines, B.; Dive, D.; Khalife, J.; Biot, C. Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. J. Med. Chem., 2009, in press.
113. Chohan, Z. H.; Scozzafava, A.; Supuran, C. T. Unsymmetrical 1,1'-disubstituted Ferrocenes: Synthesis of Co(ii), Cu(ii), Ni(ii) and Zn(ii) Chelates of Ferrocenyl -1-thiadiazolo-1'-tetrazole, -1- thiadiazolo-1'-triazole and -1-tetrazolo-1'-triazole with Antimicrobial Properties. J. Enzyme Inhib. Med. Chem., 2002, 17, 261-266.
114. Wustrow, D. J.; Capiris, T.; Rubin, R.; Knobelsdorf, J. A.; Akunne, H.; Davis, M. D.; MacKenzie, R.; Pugsley, T. A.; Zoski, K. T.; Heffner, T. G.; Wise, L. D. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg. Med. Chem. Lett., 1998, 8, 2067-2070.
115. Cecchi, L.; Melani, F.; Palazzino, G.; Filacchioni, G.; Porretta, G. C. Pyrrolnitrin analogues. IX. Synthesis and biological activity of 1-tolyl-3-nitrophenyl-5-methylpyrazole-4-carboxylic acids and 1-tolyl-3-methyl-5-nitrophenylpyrazole-4-carboxylic acids. Il FARMACO. 1984, 39, 888-900.
116. Cecchi, L.; Melani, F.; Palazzino, G.; Filacchioni, G. Pyrrolnitrin analogues. X. Synthesis and biological activity of 1-chlorophenyl- 3- or 5-nitrophenyl-pyrazole-4-carboxylic acids. Il FARMACO. 1984, 39, 953-962.
117. Küçükgüzel, G.; Rollas, S.; Erdeniz, H.; Kiraz, M.; Ekinci, A. C.; Vidin, A. Synthesis, characterization and pharmacological properties of some 4-arylhydrazono-2-pyrazoline-5-one derivatives obtained from heterocyclic amines. Eur. J. Med. Chem., 2000, 35, 761-771.
118. Genin, M. J.; Allwine, D. A.; Anderson, D. J.; Barbachyn, M. R.; Emmert, D. E.; Garmon, S. A.; Graber, D. R.; Grega, K. C.; Hester, J. B.; Hutchinson, D. K.; Morris, J.; Reischer, R. J.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; and Yagi, B. H. Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms haemophilus influenzae and moraxella. J. Med. Chem., 2000, 43
119. Fahmy, H. T. Y.; Rostom, S. A. F.; Baraka, A. M. Design and synthesis of some substituted 1H-pyrazolylthiazolo[ 4,5-d]pyrimidines as anti-inflammatory-antimicrobial Agents. Eur. J. Med. Chem., 2003, 38, 27-36.
120. Zora, M.; Gormen, M. Synthesis of ferrocenyl pyrazoles by the reaction of (2-formyl-1-chlorovinyl)ferrocene with hydrazines. J. Organomet. Chem., 2007, 692, 5026-5032.
121. Zora, M.; Pinar, A. N.; Odabaosoglu, M.; Büyükgüngör, O.; Turgut, G. Synthesis of ferrocenyl pyrazoles by the reaction of 3- ferrocenylpropynal with hydrazinium salts. J. Organomet. Chem., 2008, 693, 145-154.
122. Joksović, M.; Ratković, Z.; Vukićević, M.; Vukićević, R. D. Synthesis of 1H-3-Ferrocenyl-1-phenyl-4-substituted Pyrazoles. Synlett., 2006, 2581-2584.
123. Damljanovic, I.; Vukićević, M.; Radulović, N.; Palić, R.; Ellmerer, E.; Ratković, Z.; Joksović, M. D.; Vukićević, R. D. Synthesis and antimicrobial activity of some new pyrazole derivatives containing a ferrocene unit. Bioorg. Med. Chem. Lett., 2009, 19, 1093-1096.
124. Chantson, J. T.; Falzacappa, M. V. V.; Crovella, S.; Metzler-Nolte, N. Antibacterial activities of ferrocenoyl- and cobaltoceniumpeptide bioconjugates. J. Organomet. Chem., 2005, 690, 4564-4572.
125. Chantson, J. T.; Falzacappa, M. V. V.; Crovella, S.; Metzler-Nolte, N. Solid-phase synthesis, characterization, and antibacterial activities of metallocene-peptide bioconjugates. Chem Med Chem, 2006, 1, 1268-1274.
126. Bettinetti, L.; Schlotter, K.; Hübner, H.; Gmeiner, P. Interactive SAR studies: Rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J. Med. Chem., 2002, 45, 4594-4597.
127. Boeckler, F.; Leng, A.; Mura, A.; Bettinetti, L.; Feldon, J.; Gmeiner, P.; Ferger, B. Attenuation of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice. Biochem. Pharmacol., 2003, 66, 1025-1032.
128. Löber, S.; Hübner, H.; Utz, W.; Gmeiner, P. Rationally Based Efficacy Tuning of Selective Dopamine D4 Receptor Ligands Leading to the Complete Antagonist 2-[4-(4-Chlorophenyl) piperazin-1- ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). J. Med. Chem., 2001, 44, 2691-2694.
129. Boeckler, F.; Russig, H.; Zhang, W.; Löber, S.; Schetz, J.; Hübner, H.; Ferger, B.; Gmeiner, P.; Feldon, J. FAUC 213, a highly selective dopamine D 4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia. Psychopharmacology, 2004, 175, 7-17.
130. Schlotter, K.; Boeckler, F.; Hübner, H.; Gmeiner, P. Fancy Bioisosteres: Metallocene-derived G-Protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. J. Med. Chem., 2005, 48, 3696-3699.
131. Chen, X.; Wang, W. Chapter 32. The use of bioisosteric groups in lead optimization. Annu. Rep. Med. Chem., 2003, 38, 333-346.
132. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
133. Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019, A new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodiversity, 2008, 5, 2140-2155.
134. Bergamo, A.; Stocco, G.; Casarsa, C.; Cocchietto, M.; Alessio, E.; Serli, B.; Zorzet, S.; Sava, G. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro humour invasion. Int. J. Oncol., 2004, 24, 373-379.
135. Carmona, D.; Lamata, M. P.; Oro, L. A. Half-Sandwich complexes with aminocarboxylate ligands and their use as enantioselective hydrogen transfer catalysts. Eur. J. Inorg. Chem., 2002, 9, 2239-2251.
136. Velders, A. H.; Bergamo, A.; Alessio, E.; Zangrando, E.; Haasnoot, J. G.; Casarsa, C.; Cocchietto, M.; Zorzet, S.; Sava, G. Synthesis and Chemical-Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans- RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7- Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). J. Med. Chem., 2004, 47, 1110-1121.
137. Dale, L. D.; Tocher, J. H.; Dyson, T. M.; Edwards, D. I.; Tocher, D. A. Studies on DNA damage and induction of SOS repair by novel multifunctional bioreducible compounds. II. A metronidazole adduct of a ruthenium-arene compound. Anti-Cancer Drug Des., 1992, 7, 3-14.
138. Scolaro, C.; Geldbach, T. J.; Rochat, S.; Dorcier, A.; Gossens, C.; Bergamo, A.; Cocchietto, M.; Tavernelli, I.; Sava, G.; Rothlisberger, U.; Dyson, P. J. Influence of hydrogen-bonding substituents on the cytotoxicity of RAPTA compounds. Organometallics, 2006, 25, 756-765.
139. Ang, W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson, P. J. Development of organometallic ruthenium -arene anticancer drugs that resist hydrolysis. Inorg. Chem., 2006, 45, 9006-9013.
140. Vock, C. A. Anna K. Renfrew, Rosario Scopelliti, Lucienne Juillerat-Jeanneret, Paul J. Dyson. Influence of the diketonato ligand on the cytotoxicities of [Ru(6-p-cymene)(R2acac)(PTA)]+ complexes (PTA = 1,3,5-triaza-7-phosphaadamantane). Eur. J. Inorg. Chem., 2008, 10, 1661-1671.
141. Melchart, M.; Sadler, P. J. Bioorganometallics, ed. G. Jaouen, Wiley-VCH, Weinheim, 2006.
142. Berger, I.; Hanif, M.; Nazarov, A. A.; Hartinger, C. G.; John, R. O.; Kuznetsov, M. L.; Groessl, Michael.; Schmitt, F.; Zava, O.; Biba, F.; Arion, V. B.; Galanski, M.; Jakupec, M. A.; Juillerat-Jeanneret, L.; Dyson, P. J.; Keppler, B. K. In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chemistry, 2008, 14, 9046-9057.
143. Hartinger, C. G.; Nazarov, A. A.; Ashraf, S. M.; Dyson, P. J.; Keppler, B. K. Carbohydrate-metal complexes and their potential as anticancer agents. Curr. Med. Chem., 2008, 15, 2574-2591.
144. Habtemariam, A.; Melchart, M.; Fernández, R.; Parsons, S.; Oswald, I. D. H.; Parkin, A.; Fabbiani, F. P. A.; Davidson, J. E.; Dawson, A.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. Structure -activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem., 2006, 49, 6858-6868.
145. Vock, C. A.; Ang, W. H.; Scolaro, C.; Phillips, A. D.; Lagopoulos, L.; Juillerat-Jeanneret, L.; Sava, G.; Scopelliti, R.; Dyson, P. J. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J. Med. Chem., 2007, 50, 2166-2175.
146. Ang, W. H.; De Luca, A.; Chapuis-Bernasconi, C.; Juillerat-Jeanneret, L.; Lo Bello, M.; Dyson, P. J. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. Chem Med Chem, 2007, 2, 1799-1806.
147. Schatzschneider, U.; Metzler-Nolte, N. New principles in medicinal organometallic chemistry. Angew. Chem. Int. Ed., 2006, 45, 1504-1507.
148. Bregman, H.; Williams, D. S.; Atilla, G. E.; Carroll, P. J.; Meggers, E. An organometallic inhibitor for glycogen synthase kinase 3. J. Am. Chem. Soc., 2004, 126, 13594-13595.
149. Williams, D. S.; Atilla, G. E.; Bregman, H.; Arzoumanian, A.; Klein, P. S.; Meggers, E. Switching on a signaling pathway with an organoruthenium complex. Angew. Chem., 2005, 117, 2020-2023.
150. Williams, D. S.; Atilla, G. E.; Bregman, H.; Arzoumanian, A.; Klein, P. S.; Meggers, E. Switching on a signaling pathway with an organoruthenium complex. Angew. Chem. Int. Ed., 2005, 44, 1984-1987.
151. Debreczeni, J. E.; Bullock, A. N.; Atilla, G. E.; Williams, D. S.; Bregman, H.; Knapp, S.; Meggers, E. Ruthenium Half-Sandwich complexes bound to protein kinase Pim-1. Angew. Chem., Int. Ed., 2006, 45, 1580-1585.
152. Meggers, E.; Atilla-Gokcumen, G. E.; Bregman, H.; Maksimoska, J.; Mulcahy, S. P.; Pagano, N.; Williams, D. S. Exploring chemical space with organometallics: Ruthenium complexes as protein kinase inhibitors. Synlett, 2007, 8, 1177-1189.
153. Schmid, W. F.; John, R. O.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Highly antiproliferative ruthenium(II) and osmium(II) arene complexes with paullone-derived ligands. Organometallics, 2007, 26, 6643-6652.
154. Smalley, K. S. M.; Contractor, R.; Haass, N. K.; Kulp, A. N.; Atilla-Gokcumen, G. E.; Williams, D. S.; Bregman, H.; Flaherty, K. T.; Soengas, M. S.; Meggers, E.; Herlyn, M. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res., 2007, 67, 209-217.
155. Gaiddon, C.; Jeannequin, P.; Bischoff, P.; Pfeffer, M.; Sirlin, C.; Loeffler, J. P. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J. Pharmacol. Exp. Ther., 2005, 315, 1403-1411.
156. Van Rijt, S. H.; Peacock, A. F. A.; Johnstone, R. D. L.; Parsons, S.; Sadler, P. J. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. Inorg. Chem., 2009, 48, 1753-1762.
157. Van Rijt, S. H.; Hebden, A. J.; Amaresekera, T.; Deeth, R. J.; Clarkson, G. J.; Parsons, S.; McGowan, P. C.; Sadler, P. J. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes. J. Med. Chem., 2009, 52, 7753-7764.
158. Mendoza-Ferri, M.-G.; Hartinger, C. G.; Eichinger, R. E.; Stolyarova, N.; Severin, K.; Jakupec, M. A.; Nazarov, A. A.; Keppler, B. K. Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds. Organometallics, 2008, 27, 2405-2407.
159. Casini, A.; Hartinger, C.; Gabbiani, C.; Mini, E.; Dyson, P. J.; Keppler, B. K.; Messori, L. Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. J. Inorg. Biochem., 2008, 102, 564-575.
160. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V.H. Platinum compounds: A new class of potent antitumour agents. Nature, 1969, 222, 385-386.
161. Lippert, B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, John Wiley & Sons, Inc., New York, 1999.
162. Wong, E.; Giandomenico, C. M. Current Status Of Platinum-Based Antitumor Drugs. Chem. Rev., 1999, 99, 2451-2466.
163. Tiekink, E.R. Gold derivatives for the treatment of cancer. Crit. Rev. Oncol. Hematol., 2002, 42, 225-248.
164. Parish, R.V.; Howe, B. P.; Wright, J. P.; Mack, J.; Pritchard, R. G.; Buckley, R. G.; Elsome, A. M.; Fricker, S. P. Chemical and Biological Studies of Dichloro(2-((dimethylamino)methyl)phenyl) gold(III). Inorg. Chem., 1996, 35, 1659-1666.
165. Buckley, R. G.; Elsome, A. M.; Fricker, S. P.; Henderson, G. R.; Theobald, B. R.; Parish, R. V.; Howe, B. P.; Kelland, L. R. Antitumor Properties of Some 2-[(Dimethylamino)methyl]phenylgold (III) Complexes. J. Med. Chem., 1996, 39, 5208-5214.
166. Carotti, S.; Guerri, A.; Mazzei, T.; Messori, L.; Mini, E.; Orioli, P. Gold(III) compounds as potential antitumor agents: Cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes. Inorg. Chim. Acta, 1998, 281, 90-94.
167. Messori, L.; Abbate, F.; Marcon, G.; Orioli, P.; Fontani, M.; Mini, E.; Mazzei, T.; Carotti, S.; O'Connell, T.; Zanello, P. Gold(III) Complexes as Potential Antitumor Agents: Solution chemistry and cytotoxic properties of some selected gold(III) compounds. J. Med. Chem., 2000, 43, 3541-3548.
168. Marcon, G.; Carotti, S.; Coronnello, M.; Messori, L.; Mini, E.; Orioli, P.; Mazzei, T.; Cinellu, M. A.; Minghetti, G. Gold(III) complexes with bipyridyl ligands: Solution chemistry, cytotoxicity, and DNA binding properties. J. Med. Chem., 2002, 45, 1672-1677.
169. Coronnello, M.; Mini, E.; Caciagli, B.; Cinellu, M. A.; Bindoli, A.; Gabbiani, C.; Messori, L. Mechanisms of cytotoxicity of selected organogold(III) compounds. J. Med. Chem., 2005, 48, 6761-6765.
170. Abbate, F.; Orioli, P.; Bruni, B.; Marcon, G.; Messori, L. Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichloro(o-phenanthroline)gold(III) chloride. Inorg. Chim. Acta, 2000, 311, 1-5.
171. Kascatan-Nebioglu, A.; Panzner, M. J.; Tessier, C. A.; Cannon, C. L.; Youngs, W. J. N-Heterocyclic carbene-silver complexes: A new class of antibiotics. Coord. Chem. Rev., 2007, 251, 884-895.